TCGA-UF-A7JO-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.144063927
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- INTERFERON_GAMMA_RESPONSE+0.580
- OXIDATIVE_PHOSPHORYLATION+0.570
- MYC_TARGETS_V1+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- ALLOGRAFT_REJECTION+0.480
- MYC_TARGETS_V2+0.380
- E2F_TARGETS+0.370
- DNA_REPAIR+0.360
- COMPLEMENT+0.350
Top 10 suppressed
- UV_RESPONSE_DN-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- ANGIOGENESIS-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- MYOGENESIS-0.300
- TGF_BETA_SIGNALING-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
- APICAL_JUNCTION-0.260
- PANCREAS_BETA_CELLS-0.250
- NOTCH_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.905 |
| 2 | TCGA-T2-A6WX-01A-12R-A34R-07 | — | — | 0.876 |
| 3 | ERR2208905 | — | — | 0.876 |
| 4 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.876 |
| 5 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.868 |
| 6 | SRR8518156 | — | D | 0.868 |
| 7 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.867 |
| 8 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.866 |
| 9 | ERR2208906 | — | — | 0.863 |
| 10 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |